Chronic Kidney Disease: Management and Pathophysiology
Core Pathophysiology
CKD results from progressive nephron loss driven by glomerular hyperfiltration, podocyte injury, tubular dysfunction, inflammation, and fibrosis, with diabetes and hypertension being the leading causes worldwide 1. The pathogenic cascade involves:
- Metabolic disturbances: Chronic hyperglycemia triggers accumulation of advanced glycation end products (AGEs), polyol pathway activation, protein kinase C signaling, and mitochondrial dysfunction 2
- Hemodynamic injury: Activation of the renin-angiotensin-aldosterone system (RAAS) causes glomerular hyperfiltration and progressive damage 1, 3
- Inflammatory and fibrotic pathways: Lead to glomerular and tubulointerstitial scarring 1
- Emerging mechanisms: Ferroptosis (iron-dependent cell death), impaired autophagy, gut microbiota dysbiosis, and epigenetic alterations 2
CKD affects 8-16% of the global population and is the 16th leading cause of years of life lost worldwide 4.
Foundational Management Strategy
Blood Pressure Control
Target systolic BP <120 mmHg when tolerated using standardized office measurement 5. This aggressive target reduces cardiovascular events and slows CKD progression 3, 6.
Key considerations:
- Use less intensive targets in patients with frailty, high fall risk, limited life expectancy, or symptomatic orthostatic hypotension 5
- In children with CKD, target 24-hour mean arterial pressure ≤50th percentile for age, sex, and height using ambulatory BP monitoring 5
- Supplement office measurements with ambulatory and home BP monitoring 6
Dietary Modifications
Restrict sodium intake to <2 g/day (equivalent to <5 g sodium chloride/day) 5. This is critical for BP control and reducing proteinuria 3.
Protein intake recommendations:
- Maintain 0.8 g/kg/day in CKD G3-G5 5
- Avoid high protein intake >1.3 g/kg/day in patients at risk of progression 5
- Consider very low-protein diets (0.3-0.4 g/kg/day) supplemented with essential amino acids or ketoacid analogs in motivated patients at high risk of kidney failure, under close supervision 5
- Do not restrict protein in children due to growth impairment risk; target upper end of normal range 5
- In older adults with frailty or sarcopenia, consider higher protein and calorie targets 5
Pharmacologic Therapy: The Four Pillars
1. RAAS Inhibitors (ACEi or ARB)
Start RAAS inhibitors in all patients with CKD and albuminuria 5:
- Strong recommendation (1B): CKD G1-G4 with severely increased albuminuria (A3), with or without diabetes
- Conditional recommendation (2C): CKD G1-G4 with moderately increased albuminuria (A2) without diabetes
- Strong recommendation (1B): CKD G1-G4 with moderate-to-severe albuminuria (A2-A3) with diabetes
Critical implementation points:
- Use the highest approved tolerated dose to achieve proven trial benefits 5
- Check BP, creatinine, and potassium 2-4 weeks after initiation or dose increase 5
- Do not discontinue for hyperkalemia—manage potassium levels with dietary modification or potassium binders rather than stopping RAAS inhibitors 5
- Continue therapy unless creatinine rises significantly (specific threshold not provided in guidelines, but generally >30% increase warrants evaluation)
2. SGLT2 Inhibitors
SGLT2 inhibitors are now first-line therapy regardless of diabetes status 5:
- Strong recommendation (1A): Adults with diabetes and CKD with eGFR ≥20 ml/min/1.73 m² with urine ACR ≥200 mg/g, OR heart failure (regardless of albuminuria)
- Conditional recommendation (2B): Adults with eGFR 20-45 ml/min/1.73 m² with urine ACR <200 mg/g
Key points:
- The reversible eGFR decrease on initiation is expected and generally not an indication to discontinue 5
- Does not require alteration of CKD monitoring frequency 5
- Provides cardiovascular and kidney protection through reduction of hyperfiltration, proteinuria, inflammation, and fibrosis 1
3. Nonsteroidal Mineralocorticoid Receptor Antagonists (MRA)
Add nonsteroidal MRA (finerenone) to RAAS inhibitor and SGLT2i in type 2 diabetes with persistent albuminuria 5:
- Conditional recommendation (2A): Adults with T2D, eGFR >25 ml/min/1.73 m², normal potassium, and albuminuria >30 mg/g despite maximum tolerated RAAS inhibitor dose
- Most appropriate for patients at high risk of CKD progression and cardiovascular events with persistent albuminuria despite standard therapy 5
Hyperkalemia management protocol 5:
| Potassium Level | Action |
|---|---|
| K⁺ ≤4.8 mmol/L | Initiate finerenone: 10 mg daily if eGFR 25-59; 20 mg daily if eGFR ≥60 |
| K⁺ 4.9-5.5 mmol/L | Continue current dose; monitor K⁺ every 4 months |
| K⁺ >5.5 mmol/L | Hold finerenone; adjust diet/medications; recheck K⁺; reinitiate at 10 mg if K⁺ ≤5.0 |
- Monitor potassium at 1 month after initiation, then every 4 months 5
- Prioritize agents with documented kidney or cardiovascular benefits 5
4. GLP-1 Receptor Agonists
Use long-acting GLP-1 RA in type 2 diabetes with CKD when glycemic targets not met despite metformin and SGLT2i, or when those agents cannot be used 5:
- Strong recommendation (1B) 5
- Prioritize agents with documented cardiovascular benefits 5
- Provides cardiovascular and kidney protection beyond glycemic control 2
Additional Management Considerations
Metabolic Acidosis
- Consider pharmacological treatment with or without dietary intervention when serum bicarbonate <18 mmol/L 5
- Monitor to ensure bicarbonate does not exceed upper limit of normal and does not adversely affect BP, potassium, or fluid status 5
Hyperuricemia
- Offer uric acid-lowering therapy for symptomatic hyperuricemia (gout) 5
- Consider initiating after first gout episode, particularly if no avoidable precipitant or uric acid >9 mg/dL 5
- Prescribe xanthine oxidase inhibitors (preferred over uricosuric agents in CKD) 5
Hyperkalemia Management
- Be aware of laboratory variability and factors influencing potassium measurement (diurnal/seasonal variation, plasma vs. serum samples, medications) 5
- For CKD G3-G5 with emergent hyperkalemia: implement individualized approach with dietary and pharmacologic interventions 5
- Limit intake of foods rich in bioavailable potassium (especially processed foods) in patients with history of hyperkalemia 5
- Use potassium management strategies to avoid discontinuing prognostically beneficial medications 6
Dyslipidemia
- Treat dyslipidemia as part of cardiovascular risk reduction (statins recommended, though specific guidelines not detailed in provided evidence) 4, 7
Monitoring for CKD Complications
Monitor for and manage 4:
- Hyperkalemia
- Metabolic acidosis
- Hyperphosphatemia
- Vitamin D deficiency
- Secondary hyperparathyroidism
- Anemia
Nephrotoxin Avoidance
- Avoid NSAIDs and other nephrotoxic medications 4
- Adjust drug dosing for many antibiotics and oral hypoglycemic agents 4
Referral to Nephrology
Promptly refer patients at high risk of CKD progression 4:
- eGFR <30 ml/min/1.73 m²
- Albuminuria ≥300 mg per 24 hours
- Rapid decline in eGFR
Emerging Therapies
Investigational agents under evaluation include 1, 2:
- Endothelin receptor antagonists
- Angiotensin receptor-neprilysin inhibitors
- Nrf2 activators
- Aldosterone synthase inhibitors
- Gut microbiota modulators
Critical Pitfalls to Avoid
- Do not discontinue RAAS inhibitors for mild hyperkalemia—manage potassium levels instead 5, 6
- Do not stop SGLT2i for initial eGFR dip—this is expected and reversible 5
- Do not restrict protein in children—risk of growth impairment 5
- Do not prescribe low-protein diets in metabolically unstable patients 5
- Do not restrict sodium in sodium-wasting nephropathy 5
- Do not underestimate cardiovascular risk—CVD is the major cause of mortality in CKD 3, 7
Combination Therapy Advantage
Meta-analyses demonstrate that combination therapy with SGLT2 inhibitors, GLP-1 RA, and nonsteroidal MRA can extend cardiovascular and kidney event-free survival by 3-5 years in high-risk patients with type 2 diabetes 8. Simultaneous modulation of multiple pathogenic pathways provides superior cardiorenal protection compared to monotherapy 2.